GlaxoSmithKline plc (LON:GSK) had its price objective trimmed by J P Morgan Chase & Co from GBX 1,570 ($20.72) to GBX 1,330 ($17.55) in a research note released on Sunday morning, StockTargetPrices.com reports. The brokerage currently has a neutral rating on the stock.
Several other equities research analysts have also commented on GSK. Barclays PLC reiterated an equal weight rating and set a GBX 1,550 ($20.45) price target on shares of GlaxoSmithKline plc in a research note on Monday, July 3rd. Citigroup Inc. lowered shares of GlaxoSmithKline plc from a buy rating to a neutral rating and set a GBX 1,700 ($22.43) price target on the stock. in a research note on Wednesday, July 5th. Jefferies Group LLC reiterated a buy rating and set a GBX 1,900 ($25.07) price target on shares of GlaxoSmithKline plc in a research note on Thursday, July 13th. Shore Capital reiterated a hold rating on shares of GlaxoSmithKline plc in a research note on Friday, July 14th. Finally, Morgan Stanley reiterated an equal weight rating and set a GBX 1,700 ($22.43) price target on shares of GlaxoSmithKline plc in a research note on Tuesday, July 18th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and six have assigned a buy rating to the company. GlaxoSmithKline plc currently has an average rating of Hold and an average target price of GBX 1,623.50 ($21.42).
GlaxoSmithKline plc (LON GSK) opened at 1357.50 on Friday. GlaxoSmithKline plc has a 12 month low of GBX 1,347.00 and a 12 month high of GBX 1,724.50. The stock’s 50 day moving average price is GBX 1,484.09 and its 200-day moving average price is GBX 1,568.30. The firm’s market capitalization is GBX 66.35 billion.
GlaxoSmithKline plc (LON:GSK) last announced its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). GlaxoSmithKline plc had a negative net margin of 1.17% and a negative return on equity of 57.19%. The firm had revenue of GBX 784.30 billion for the quarter. Equities analysts forecast that GlaxoSmithKline plc will post $110.55 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/11/01/j-p-morgan-chase-co-trims-glaxosmithkline-plc-gsk-target-price-to-gbx-1330.html.
In related news, insider Simon Dingemans acquired 1,076 shares of the firm’s stock in a transaction that occurred on Thursday, October 12th. The shares were purchased at an average price of GBX 1,527 ($20.15) per share, with a total value of £16,430.52 ($21,681.87). Also, insider Urs Rohner acquired 473 shares of the firm’s stock in a transaction that occurred on Wednesday, October 25th. The shares were bought at an average cost of GBX 1,518 ($20.03) per share, for a total transaction of £7,180.14 ($9,474.98). In the last three months, insiders have purchased 1,574 shares of company stock worth $2,398,888.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.